m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG01243)
Name
SAR-125844
Synonyms
Met inhibitor (iv, cancer), sanofi-aventis
    Click to Show/Hide
Status
Phase 2
Structure
Formula
C25H23FN8O2S2
InChI
1S/C25H23FN8O2S2/c26-17-3-1-16(2-4-17)19-7-8-22-30-31-25(34(22)32-19)37-18-5-6-20-21(15-18)38-24(28-20)29-23(35)27-9-10-33-11-13-36-14-12-33/h1-8,15H,9-14H2,(H2,27,28,29,35)
InChIKey
ODIUNTQOXRXOIV-UHFFFAOYSA-N
PubChem CID
25182860
TTD Drug ID
D07ARN
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Proto-oncogene c-Met (MET)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Proto-oncogene c-Met (MET) is a therapeutic target for SAR-125844. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SAR-125844 through regulating the expression of Proto-oncogene c-Met (MET). [1], [2]
References
Ref 1 RNA m(6) A methylation regulates uveal melanoma cell proliferation, migration, and invasion by targeting c-Met. J Cell Physiol. 2020 Oct;235(10):7107-7119. doi: 10.1002/jcp.29608. Epub 2020 Feb 4.
Ref 2 A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors. Oncotarget. 2015 Jul 30;6(21):18693-706. doi: 10.18632/oncotarget.4472.